Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell Lines
Open Access
- 15 May 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (10) , 3327-3332
- https://doi.org/10.1158/1078-0432.ccr-03-0820
Abstract
Purpose: Vascular endothelial growth factor A (VEGF-A) is a potent angiogenic agent that binds to two high affinity VEGF receptors (VEGFRs), a process facilitated by the low affinity neuropilin receptors. Although VEGF-A is overexpressed in pancreatic ductal adenocarcinoma, it is not known whether the in vivo growth of multiple pancreatic cancer cells can be efficiently blocked by VEGF-A sequestration. Experimental Design: Four human pancreatic cancer cell lines were grown s.c. in athymic nude mice. One cell line also was used to generate an orthotopic model of metastatic pancreatic cancer. The consequences of VEGF-A sequestration on tumor growth and metastasis were examined by injecting the mice with a soluble VEGFR chimer (VEGF-Trap) that binds VEGF-A with high affinity. Results: VEGF-Trap, initiated 2 days after tumor cell inoculation, suppressed the s.c. growth of four pancreatic cancer cell lines and markedly decreased tumor microvessel density. Analysis of RNA from tumors generated with T3M4 cells revealed that VEGF-Trap decreased the expression of VEGFR-1 and neuropilin-1 and -2. VEGF-Trap, initiated 3 weeks after tumor implantation, also attenuated intrapancreatic tumor growth and metastasis in an orthotopic model using PANC-1 cells. Conclusions: VEGF-Trap is a potent suppressor of pancreatic tumor growth and metastasis and also may act to attenuate neuropilin-1 and -2 and VEGFR-1 expression. Therefore, VEGF-Trap may represent an exceedingly useful therapeutic modality for pancreatic ductal adenocarcinoma.Keywords
This publication has 47 references indexed in Scilit:
- Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptorCancer Gene Therapy, 2002
- Inhibition of Growth and Metastasis of Human Pancreatic Cancer Growing in Nude Mice by PTK 787/ZK222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine KinasesCancer Biotherapy & Radiopharmaceuticals, 2001
- Pancreatic cancer cell-derived vascular endothelial growth factor is biologically activein vitro and enhances tumorigenicityin vivoInternational Journal of Cancer, 2001
- Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121Journal of Biological Chemistry, 2001
- The interaction of Neuropilin-1 with Vascular Endothelial Growth Factor and its receptor Flt-1Journal of Biological Chemistry, 2000
- Radiation Therapy in Pancreatic CancerJournal of Clinical Gastroenterology, 2000
- Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancerInternational Journal of Cancer, 1999
- Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.Journal of Clinical Investigation, 1998
- VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular MatrixJournal of Biological Chemistry, 1997
- Pancreatic CarcinomaNew England Journal of Medicine, 1992